Header logo

NRAS (p.Q61L)

Variant Data

Location

  • HGVS: ENST00000369535:c.182A>T
  • Reference Version: GRCh37
  • Chromosome: 1
  • Start: 115256529
  • Stop: 115256529
  • Strand: -1
  • Transcript: ENST00000369535 (ensembl - 74_37)
  • Gene: NRAS ( View drug interactions on DGIdb )

Information

Disease Data

Disease Source Batch Tags External Links
melanoma van 't Veer et al., 1989, Mol. Cell. Biol. My Cancer Genome (View variants) pathogeniclikely pathogenic My Cancer Genome
melanoma Ball et al., 1994, J. Invest. Dermatol. My Cancer Genome (View variants) pathogeniclikely pathogenic My Cancer Genome
non-small cell lung carcinoma Brose et al., 2002, Cancer Res. My Cancer Genome (View variants) pathogenic My Cancer Genome
melanoma Curtin et al., 2005, N. Engl. J. Med. My Cancer Genome (View variants) pathogeniclikely pathogenic My Cancer Genome
melanoma Adjei et al., 2008, J. Clin. Oncol. My Cancer Genome (View variants) pathogeniclikely pathogenic My Cancer Genome
non-small cell lung carcinoma Ding et al., 2008, Nature My Cancer Genome (View variants) pathogenic My Cancer Genome
melanoma Hatzivassiliou et al., 2010, Nature My Cancer Genome (View variants) pathogeniclikely pathogenic My Cancer Genome
melanoma Poulikakos et al., 2010, Nature My Cancer Genome (View variants) pathogeniclikely pathogenic My Cancer Genome
melanoma Martinez-Garcia et al., 2012, Clin. Cancer Res. My Cancer Genome (View variants) pathogeniclikely pathogenic My Cancer Genome
melanoma Ascierto et al., 2013, Lancet Oncol. My Cancer Genome (View variants) pathogeniclikely pathogenic My Cancer Genome
non-small cell lung carcinoma Ohashi et al., 2013, Clin. Cancer Res. My Cancer Genome (View variants) pathogenic My Cancer Genome
melanoma Haarberg et al., 2013, Mol. Cancer Ther. My Cancer Genome (View variants) pathogeniclikely pathogenic My Cancer Genome
melanoma Trunzer et al., 2013, J. Clin. Oncol. My Cancer Genome (View variants) pathogeniclikely pathogenic My Cancer Genome
melanoma Morris et al., 2013, Cancer Discov My Cancer Genome (View variants) pathogeniclikely pathogenic My Cancer Genome
melanoma Halaban et al., 2010, Pigment Cell Melanoma Res Literature (View variants) likely pathogenic
melanoma Søndergaard et al., 2010, J Transl Med Literature (View variants) likely pathogenic
melanoma MacConaill et al., 2014, J Mol Diagn Oncomap Variants (View variants) likely pathogenic
skin melanoma Chang et al., 2016, Nat. Biotechnol. Pan-cancer recurrent hotspots (View variants) likely pathogenic
thyroid carcinoma Chang et al., 2016, Nat. Biotechnol. Pan-cancer recurrent hotspots (View variants) likely pathogenic
multiple myeloma Chang et al., 2016, Nat. Biotechnol. Pan-cancer recurrent hotspots (View variants) likely pathogenic
colorectal cancer Chang et al., 2016, Nat. Biotechnol. Pan-cancer recurrent hotspots (View variants) likely pathogenic
acute myeloid leukemia Chang et al., 2016, Nat. Biotechnol. Pan-cancer recurrent hotspots (View variants) likely pathogenic
uterine corpus endometrial carcinoma Chang et al., 2016, Nat. Biotechnol. Pan-cancer recurrent hotspots (View variants) likely pathogenic
lung adenocarcinoma Chang et al., 2016, Nat. Biotechnol. Pan-cancer recurrent hotspots (View variants) likely pathogenic
chronic lymphocytic leukemia Chang et al., 2016, Nat. Biotechnol. Pan-cancer recurrent hotspots (View variants) likely pathogenic
urinary bladder urothelial carcinoma Chang et al., 2016, Nat. Biotechnol. Pan-cancer recurrent hotspots (View variants) likely pathogenic
gastric adenocarcinoma Chang et al., 2016, Nat. Biotechnol. Pan-cancer recurrent hotspots (View variants) likely pathogenic
ovarian serous cystadenocarcinoma Chang et al., 2016, Nat. Biotechnol. Pan-cancer recurrent hotspots (View variants) likely pathogenic
nasopharynx carcinoma Chang et al., 2016, Nat. Biotechnol. Pan-cancer recurrent hotspots (View variants) likely pathogenic
hepatocellular carcinoma Chang et al., 2016, Nat. Biotechnol. Pan-cancer recurrent hotspots (View variants) likely pathogenic
brain glioma Chang et al., 2016, Nat. Biotechnol. Pan-cancer recurrent hotspots (View variants) likely pathogenic
chromophobe adenocarcinoma Chang et al., 2016, Nat. Biotechnol. Pan-cancer recurrent hotspots (View variants) likely pathogenic
glioblastoma multiforme Chang et al., 2016, Nat. Biotechnol. Pan-cancer recurrent hotspots (View variants) likely pathogenic
adrenocortical carcinoma Chang et al., 2016, Nat. Biotechnol. Pan-cancer recurrent hotspots (View variants) likely pathogenic
melanoma Soon et al., 2011, Arch Dermatol CIViC Knowledgebase (View variants) Civic logo CIViC

Drug Interaction Data

Therapeutic Context Pathway Effect Association Status Evidence Source
MEK inhibitors activation gain-of-function late trials emerging 23414587
MEK inhibitors activation gain-of-function early trials emerging 18390968, 22761467
MEK inhibitors + CDK4/6 inhibitors activation gain-of-function early trials emerging ASCO 2014; abstr 9009
HSP90 inhibitors activation gain-of-function preclinical emerging 23538902
BRAF inhibitors activation gain-of-function case report emerging 23569304.0
preclinical activation gain-of-function preclinical emerging 23614898
Produced by The McDonnell Genome Institute at the Washington University School of Medicine

DoCM by The McDonnell Genome Institute at Washington University School of Medicine is licensed under a Creative Commons Attribution 4.0 International License. Questions? Comments? Concerns? You can contact us here.